3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) plus nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
ANNALS OF ONCOLOGY(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要